FDA Eases Monitoring Burden For Kidney Disease Patients On Travere Therapeutics' Filspari
The U.S. Food and Drug Administration (FDA) on Wednesday approved updated Risk Evaluation and Mitigation Strategy (REMS) labeling for Travere Therapeutics, Inc.’s (NASDAQ:TVTX) Filspari (sparsentan), the only Dual Endothelin Angiotensin Receptor Antagonist for IgA nephropathy (IgAN).
Benzinga ·
Benzinga
International Business Times
